{
    "project_id": "171230",
    "broad_study_type": "trial",
    "narrow_study_type": "randomized_controlled_trial",
    "trial_phase": "3",
    "observational_timeframe": "N/A",
    "justification": "This proposal outlines a double-blind, randomized, placebo-controlled trial to assess the effectiveness and safety of extended-release quetiapine fumarate (quetiapine XR) as monotherapy for generalized anxiety disorder (GAD).",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "The goal is to provide new information for clinicians about the risks and benefits of quetiapine XR, an important treatment option for patients with GAD.",
    "replication_study": "no",
    "target_population_size": "951",
    "age_range": "adults",
    "gender_focus": "mixed",
    "vulnerable_populations": "yes",
    "rare_disease": "no",
    "population_description": "adults with a primary diagnosis of GAD",
    "intervention_category": "drug",
    "intervention_name": "quetiapine XR",
    "control_type": "placebo",
    "dose_response": "yes",
    "combination_therapy": "no",
    "personalized_medicine": "no",
    "primary_outcome": "change from baseline in total score on the Hamilton Anxiety Rating Scale (HAM-A)",
    "primary_outcome_type": "symptom_score",
    "safety_focus": "yes",
    "quality_of_life": "yes",
    "biomarker_endpoints": "no",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "yes",
    "real_world_evidence": "no",
    "industry_partnership": "yes",
    "patient_engagement": "yes",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "yes",
    "international_network": "yes",
    "regulatory_pathway": "yes",
    "ethics_focus": "yes",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "mental_health",
    "disease_stage": "unclear",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "short_term",
    "multicenter": "yes",
    "healthcare_setting": "outpatient",
    "disease_area": "generalized anxiety disorder",
    "methodology_innovation": "double-blind, randomized, placebo-controlled trial of extended-release quetiapine fumarate for generalized anxiety disorder, with a dose-response evaluation",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 